Through week 8, the incidence of adverse events was generally similar among groups ( Table 3) . A rash occurred in 8% of patients receiving A. paniculata and 1% of patients receiving placebo. The rashes were mostly mild (with the rest moderate), reversible, and did not cause treatment discontinuation.